CA19-9, primarily a pancreatic cancer marker, exhibits low sensitivity for CRC (26–48%), whereas CEA is more useful for post-treatment monitoring and detecting disease recurrence [41]. Here, CEACAM5 is linked to colorectal carcinoma.